

688177



1

<http://www.sse.com.cn/>

2

3

4

5

6

☐ √

7

2023

8

☐ √

1

√ ☐

A			688177	

☐ $\sqrt{\quad}$

11 A6

11 A6

治疗领域	品种	适应症	靶点	药物分类	临床前	I期临床	II期临床	III期临床	NDA	上市
		银屑病、强直性脊柱炎、类风湿性关节炎、克罗恩病、溃疡性结肠炎	IL-17A	生物类似药						
获批	施瑞立®	类风湿性关节炎、银屑病、强直性脊柱炎、克罗恩病、溃疡性结肠炎	IL-17A	生物类似药					全球开发，中国NMPA、美国FDA已	
	BAT2506	类风湿性关节炎、银屑病、强直性脊柱炎	TNF-α	生物类似药					国际III期临床	
	BAT2206	银屑病、银屑病关节炎、克罗恩病、溃疡性结肠炎	IL-12 和 IL-23	生物类似药					国际III期临床	
自身抗体	BAT4406F	视神经脊髓炎	CD20	创新药/单抗						
	BAT2306	银屑病、银屑病关节炎、强直性脊柱炎、非射线照射难治性银屑病、附着点炎相关关节炎	IL-17A	生物类似药					国际III期临床	
	BAT2606	哮喘、慢性鼻炎伴鼻息肉等	IL-5	生物类似药						
	BAT6026	特应性皮炎	OX40	创新药/单抗						
	BAT2406	多种自身免疫性疾病	靶点未批露	生物类似药						
	BAT3306	癌症	PD-1	生物类似药						
	BAT4306F	CD20阳性B细胞非霍奇金淋巴瘤	CD20	创新药/单抗						
	BAT1308	PD-L1阳性持续、复发或转移性宫颈癌	PD-1联合VEGF	创新药/单抗						
	BAT1006	HER2阳性实体瘤	HER2	创新药/单抗						
	BAT4706	实体瘤	CTLA-4/Tregs	创新药/单抗						
	BAT6005	癌症	TIGIT	创新药/单抗						
	BAT7104	癌症	PD-L1/CD47	创新药/双特异抗体						
	BAT7205	癌症	PD-L1/IL-15	创新药/双功能抗体融合蛋白						
	BAT8006	癌症	FRα	创新药/ADC						
	BAT8010	癌症	HER2	创新药/ADC						
	BAT8008	癌症	Trop2	创新药/ADC						
	BAT8007	癌症	Nectin-4	创新药/ADC						
	BAT2094	PCI围术期抗血栓	β3整合素受体	创新药/类多肽						
	BAT5906	湿性老年黄斑变性、糖尿病性黄斑水肿	VEGF	创新药/单抗						

BAT1406

®

®

2019 11

®

CHO

TNF-


TNF-

TNF-

2023 12 31

®

40mg/0.8mL 20mg/0.4mL



BAT1706

®

Avzivi®

BAT1706

NMPA

FDA

EMA

(VEGF)

VEGF

VEGF

BAT1706

2021 11

®

2023 12

FDA

Avzivi®

BAT1706

EMA

Avzivi®

FDA

FDA

2023 12 31

®

Avzivi®

400mg/16mL 100mg/4mL



BAT1706

Sandoz AG

BAT1706

Cipla Gulf FZ LLC

Biommm S.A.

Mega Lifesciences

Macter International Limited

BAT1806

®

TOFIDENCE

BAT1806

NMPA

FDA

EMA

-6

IL-6R

IL-6

sIL-6R

mIL-6R

sIL-6R

mIL-6R

BAT1806

2023

1

®

®

BAT1806

2023

9

FDA

TOFIDENCE

TOFIDENCE

FDA

FDA

FDA

BAT1806

EMA

2023

12

31

®

TOFIDENCE

400mg/20mL

80mg/4mL



Biogen International GmbH 2021 4

BAT1806 TOFIDENCE

Biogen International GmbH

BAT2094

Iib/IIIa

Von Willebrand

BAT2506

III

BAT2506

TNF-

ADA

Pharmapark LLC BAT2506

BAT2206

III

BAT2206

NMPA

FDA

EMA

IL-12

IL-23

p40

IL-12

IL-23

p40

IL-12

IL-23

Hikma Pharmaceuticals USA Inc.

BAT2206

Hikma

Pharmapark LLC

BAT2206

2

CRO

3

CMC

4

FDA


4

10

2023

CSO

GSP



BAT1706

Sandoz AG

BAT1706

Avzivi®

BAT1706

Sandoz AG

Cipla Gulf FZ LLC

BAT1706

Biommm S.A.

BAT1706

Mega Lifesciences

BAT1706

BAT1706

Macter International

Limited

BAT1706

Biogen International GmbH

BAT1806

TOFIDENCE

Biogen

Hikma Pharmaceuticals USA Inc.

BAT2206

Pharmapark LLC

BAT2206

BAT2506

1.

2012

C27

2022

“

”

1

2024

1

2023

65

2021

7.61

2050

16

2023

60 29,697 21.1% 65 21,676
15.4%


2018 1.3
2022 1.5 2030 2.1
2022 1.6 2026 2.1 2022 2026
7.8% 2030 2.6

2018 2,611 2022 3,638
8.6% 2026 5,809
2030 7,832 2022 2026
12.4% 2026 2030 7.8%

2018-2030E

时期	复合年增长率
2018-2022	8.6%
2022-2026E	12.4%
2026E-2030E	7.8%

单位：十亿美元



21 2018 2022
2,622 4,210 12.6% 2026
7,698 2030 11,491 2022 2026
16.3% 2026 2030 10.5%

2018-2030E

2.

®				2019	11		
					2020	1	®
		®					
1,000			1200				
BAT1706				FDA		Avzivi®	Avzivi®
			FDA				
BAT1706				BAT1706		2021	11
		®					
	®						
BAT1806			2023	1			®
®							BAT1806
	2023	9		FDA		TOFIDENCE	TOFIDENCE
		FDA			FDA		
				FDA			BAT1806

EMA®

100

300 Biogen International GmbH

TOFIDENCE Biogen International GmbH

IDEAL Intelligent Design and Engineered Antibody Libraries IDEAL

PD-1 HER2 CTLA4 TIGIT OX40 BAT7104 CD47 PD-L1

ADC

2

2024

3.

“ ”

2022

5 2022

2023 3

2024 2 2023 2023

35.84%

28.80% 2023 1 40 19

16 5

2017-2021				
4		2020	357.30	2021
	1,871.96	400%		2023

License-out

2023

3

3.1

	2023	2022	(%)	2021
	2,287,097,856.78	2,179,736,935.85	4.93	2,617,782,079.77
	1,212,715,420.61	1,607,255,215.08	-24.55	2,087,512,209.71
	704,794,652.84	455,131,950.13	54.86	836,578,620.84
	704,412,487.54	455,128,647.38	54.77	836,578,620.84
	-394,531,428.45	-480,398,851.59		81,936,544.64
	-471,830,530.42	-522,645,205.81		35,923,321.89
	-460,870,561.93	-412,817,526.81		236,270,932.55
	-27.98	-26.01	1.97	4.00

%				
	-0.95	-1.16		0.20
	-0.95	-1.16		0.20
%			26.37	

3.2

	1-3	4-6	7-9	10-12
	154,927,728.15	159,738,745.66	146,383,740.09	243,744,438.94
	-142,584,813.68	-111,036,059.58	-128,559,363.86	-12,351,191.33
	-169,977,577.57	-116,400,723.88	-133,169,782.88	-52,282,446.09
	-146,153,513.54	-72,533,372.05	-139,459,294.51	-102,724,381.83

☐ ☒


4

4.1

:

()	7,927
()	7,424
	0
	0
	0
	0

[illegible]



4.4

☐ √

5

☐ √

1

2

☐ √